Clinical trials: Exercise Metabolism
Obesity, Obesity, Abdominal
Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study
Forty women aged between 18 and 75 years-old with a BMI> 30kg/m2 are recruited to participate in the evaluation of their medical management.
- Conditions
- Obesity, Obesity, Abdominal, Obesity, Visceral, Female
- Trial name
- PPAR-NAPAS (NCT04436419)
- Testing
- Alpha lipoic acid (plus full hospitalization)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Fauqué
Cardiovascular Disease, Diabetes
Diet and Activity Promotion Among Older Working Adults
The trial will test whether the Alive email-delivered health behavior program can improve subjects' physical activity, fruits and vegetables and saturated/trans fats and added sugars.
- Conditions
- Cardiovascular Disease, Diabetes, Obesity, Aging
- Trial name
- ALIVE (NCT01233063)
- Testing
- Physical Activity and Diet Intervention via Alive2
- Where
- United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- Berkeley Analytics, Inc.
Obesity
Use of the Incisionless Operating Platform as a Primary Treatment for Obesity vs. Diet-Exercise Alone
This study is a multi-center, open/unblended study (3:1Treatment: Control) to evaluate the safety and effectiveness of the g-Cath EZ Suture Anchor Delivery Catheter as an early weight loss intervention compared to a diet and…
- Trial name
- MILEPOST (NCT01843231)
- Testing
- g-CathTM EZ Suture Anchor Delivery Catheter, Diet and Exercise Control Group
- Where
- 3 sites in Austria, Netherlands and 1 more
- Volunteers
- 40 people
- Sponsor
- USGI Medical
Diabetes Mellitus, Type 2
Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)
The purpose of the study is to assess how MK0767, compared to Metformin, performs in lowering blood glucose levels in patients whose Type II diabetes is not controlled by diet and exercise.
- Trial name
- NCT00543361
- Testing
- MK0767, Comparator: metformin
- Volunteers
- 382 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Impact of Body Composition and Exercise on Clinical, Metabolic and Molecular Parameters in Type 2 Diabetics in Qatar
The prevalence of type 2 diabetes (T2DM) is increasing sharply around the world and obesity and sedentary lifestyles are driving the epidemic. Obesity is often, but not always present in patients with T2DM.
- Trial name
- NCT04081064
- Testing
- 10-week exercise programme based on aerobic interval and resistance training
- Where
- Qatar
- Volunteers
- 60 people
- Sponsor
- Hamad Medical Corporation
Obesity
Effects of PrimaVie and Exercise Training on Human Skeletal Muscle (PrimaVie)
PrimaVie (Natreon Inc), is a a purified and standardized shilajit extract for nutraceutical use. Research indicates that PrimaVie® has targeted action for increasing energy, revitalization and anti-aging.
- Trial name
- NCT02026414
- Testing
- PrimaVie, Exercise
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Sanni Raju
Type 2 Diabetes
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
The purpose of this study is to assess the efficacy of Yogliptin (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of Yogliptin in Chinese patients with Type 2 diabetes who are insufficient…
- Trial name
- NCT05318326
- Testing
- Yogliptin 400mg group, Yogliptin 200mg group
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
Type 2 Diabetes Mellitus
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
The purpose of this study was to evaluate the efficacy and safety of 24-week treatment with metformin hydrochloride 500 mg once daily added on to alogliptin (SYR-322) 25 mg in type 2 diabetic patients with inadequate glycemic…
- Trial name
- NCT02068443
- Testing
- Alogliptin, Metformin hydrochloride
- Where
- 27 sites in Japan
- Volunteers
- 374 people
- Sponsor
- Takeda
Type 2 Diabetes
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo.
- Trial name
- CMAP (NCT02121717)
- Testing
- Chiglitazar
- Where
- 26 sites in China
- Volunteers
- 535 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Type 2 Diabetes
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of HS-20094 injection in subjects with type 2 diabetes who have inadequate glycemic control with…
- Trial name
- NCT07156500
- Testing
- HS-20094 Injection
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Glucose Homeostasis
Comparison of the Effects of a 12-Week Consumption of Two Carbonated Beverages on Insulin Sensitivity
The purpose of this study is to determine whether consumption of carbonated drinks containing sweeteners affect insulin sensitivity.
- Trial name
- SEDULC (NCT02031497)
- Testing
- Drink with sweeteners, Drink without sweeteners
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institute For European Expertise in Physiology
Type 2 Diabetes
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- NCT07193459
- Testing
- HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
- Trial name
- NCT00374907
- Testing
- Saxagliptin, Metformin (blinded), Metformin (open-label)
- Where
- 3 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
The purpose of this study was to compare effect of Saxagliptin as add-on to Metformin on 24-hour mean weighted glucose (MWG) to the effect of uptitrating Metformin in subjects with T2DM inadequately controlled on metformin alone.
- Trial name
- NCT00918138
- Testing
- Saxagliptin, Metformin XR
- Where
- 21 sites in United States, Argentina and 2 more
- Volunteers
- 219 people
- Sponsor
- AstraZeneca
Dehydration
Utility of Transdermal Optical Imaging (TOI) as a Non-invasive Measure of Hydration Status: Phase 3a for Model Development
The primary objective of this study is to analyze smart phone-based Transdermal Optical Imaging (TOI) features to develop a model that can discern hypohydration from euhydration status including 1) a small feasibility study for…
- Trial name
- NCT06044610
- Testing
- GENPOP Passive dehydration (75% reduction in fluid intake, GENPOP Ad lib fluid intake, EXERCISE without fluid replacement
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Mucopolysaccharidosis IVA, Morquio A Syndrome
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01609062
- Testing
- BMN 110
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 25 people
- Sponsor
- BioMarin Pharmaceutical
Diabetes
HEdia eXercise Algorithm - HEXA Study.
A randomised controlled crossover pilot study to evaluate safety and efficacy of a digital insulin bolus calculator with a physical activity module
- Trial name
- NCT05458167
- Testing
- Hedia Diabetes Assistant bolus calculator with a physical activity module
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Hedia ApS
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
This study is a multicenter, randomized, double-blind (with open-label dose levels and active comparator), parallel-group, placebo- and active-controlled Phase 2 clinical trial aimed at evaluating the efficacy, safety…
- Trial name
- NCT07109700
- Testing
- HDM1005 1, HDM1005 2, HDM1005 3
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
This is the first phase 3 randomized, double-blind, placebo/active-controlled clinical study to evaluate the efficacy and long-term safety of SAL067 in treatment-naive T2DM patients uncontrolled with diet and exercise…
- Trial name
- NCT05782192
- Testing
- SAL067, Alogliptin
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Diabetic Cardiomyopathies
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.
- Trial name
- NCT04083339
- Testing
- AT-001
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 675 people
- Sponsor
- Applied Therapeutics, Inc.